Inovio Reports Positive Results from DNA Vaccine Study

11 May 2011 (Last Updated May 11th, 2011 18:30)

Inovio Pharmaceuticals has reported positive results from a Phase I study of VGX-3100, a DNA vaccine that achieved long-term durability of immune responses for treating cervical dysplasia and cancer caused by human papillomavirus. The study involved 18 women with moderate or severe cerv

Inovio Pharmaceuticals has reported positive results from a Phase I study of VGX-3100, a DNA vaccine that achieved long-term durability of immune responses for treating cervical dysplasia and cancer caused by human papillomavirus.

The study involved 18 women with moderate or severe cervical intraepithelial neoplasia; 91% of evaluated patients displayed strong and persistent memory T-cell responses at month nine.

The generation of T-cell responses indicate the disappearance of cancerous cells from the body.

Inovio Pharmaceuticals president and CEO J Joseph Kim said that, based on the data obtained in the study, the company plans to evaluate the efficacy of VGX-3100 delivered using a Cellectra electroporation device in a randomised, placebo-controlled and double-blind Phase II trial.